SH PHARMA (02607) · Company profile · Eqvero

SH PHARMA

02607HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	282.55 bn CNY	274.19 bn CNY	259.15 bn CNY	231.98 bn CNY	215.04 bn CNY
Cost of revenue	250.34 bn CNY	242.46 bn CNY	227.23 bn CNY	199.43 bn CNY	185.36 bn CNY
Research and development expense	2.34 bn CNY	2.39 bn CNY	2.2 bn CNY	2.11 bn CNY	1.99 bn CNY
Selling, general and administrative expense	18.46 bn CNY	18.33 bn CNY	19.53 bn CNY	19.17 bn CNY	18.38 bn CNY
Operating profit after depreciation	8.46 bn CNY	8.75 bn CNY	8.58 bn CNY	8.16 bn CNY	7.47 bn CNY
Operating profit before depreciation	11.32 bn CNY	11.12 bn CNY	10.71 bn CNY	10.33 bn CNY	9.53 bn CNY
EBIT	8.46 bn CNY	8.75 bn CNY	8.58 bn CNY	8.16 bn CNY	7.47 bn CNY
EBITDA	11.32 bn CNY	11.12 bn CNY	10.71 bn CNY	10.33 bn CNY	9.53 bn CNY
Interest expense	1.7 bn CNY	1.86 bn CNY	1.88 bn CNY	1.69 bn CNY	1.52 bn CNY
Profit before tax	9.82 bn CNY	8.02 bn CNY	7.05 bn CNY	8.81 bn CNY	8.14 bn CNY
Income tax expense	2.85 bn CNY	2.15 bn CNY	1.89 bn CNY	1.82 bn CNY	1.87 bn CNY
Income before extraordinary items	5.72 bn CNY	4.55 bn CNY	3.77 bn CNY	5.62 bn CNY	5.09 bn CNY
Common dividends	1.74 bn CNY	1.37 bn CNY	1.52 bn CNY	2.26 bn CNY	1.19 bn CNY
Total dividends	1.74 bn CNY	1.37 bn CNY	1.52 bn CNY	2.26 bn CNY	1.19 bn CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.